Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells
- PMID: 12692261
Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells
Abstract
Multidrug resistant (MDR) cancer cells overexpressing P-glycoprotein (P-gp) display variations in invasive and metastatic behavior. We previously reported that these properties of MDR cancer cell lines overexpressing P-gp could be altered by chemotherapeutic drugs or MDR modulators (R. S. Kerbel et al., Cancer Surv., 7: 597-629, 1988). To attempt to clarify the mechanism(s) underlying these observations, we studied the expression of extracellular matrix metalloproteinase inducer (EMMPRIN), a glycoprotein enriched on the surface of tumor cells that can stimulate the production of matrix metalloproteinases (MMPs), in sensitive and MDR cancer cells. Using immunofluorescence staining and fluorescence-activated cell sorting analysis, we found that EMMPRIN expression was increased in MDR carcinoma cell lines, MCF-7/AdrR, KBV-1, and A2780Dx5, as compared to their parental counterparts. The MDR cell lines produced more matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9), as determined by zymography, Western blot, and reverse transcription-PCR. Treatment of MDR cells with an anti-EMMPRIN antibody inhibited the activity of MMP-1, MMP-2, and MMP-9. In MDR cell line MCF-7/AdrR, an increased in vitro invasive ability was observed as compared with the sensitive line MCF-7, and EMMPRIN antibody could inhibit the in vitro invasion in drug-resistant cells. In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk). Our results suggest that during the development of MDR, the expression of EMMPRIN is responsible for the increased activity of MMP in MDR cell lines.
Similar articles
-
Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN.Mol Cancer Res. 2004 Feb;2(2):73-80. Mol Cancer Res. 2004. PMID: 14985463
-
(-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.Biosci Rep. 2011 Apr;31(2):99-108. doi: 10.1042/BSR20090143. Biosci Rep. 2011. PMID: 20446926
-
Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer.World J Surg. 2000 Mar;24(3):334-40. doi: 10.1007/s002689910053. World J Surg. 2000. PMID: 10658069
-
EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair.Biochimie. 2005 Mar-Apr;87(3-4):361-8. doi: 10.1016/j.biochi.2004.09.023. Biochimie. 2005. PMID: 15781323 Review.
-
Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function.Curr Top Dev Biol. 2003;54:371-89. doi: 10.1016/s0070-2153(03)54015-7. Curr Top Dev Biol. 2003. PMID: 12696756 Review. No abstract available.
Cited by
-
A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma.Oral Oncol. 2013 Oct;49(10):991-7. doi: 10.1016/j.oraloncology.2013.07.006. Epub 2013 Aug 3. Oral Oncol. 2013. PMID: 23920309 Free PMC article.
-
Proteomics characterization of cell membrane blebs in human retinal pigment epithelium cells.Mol Cell Proteomics. 2009 Oct;8(10):2201-11. doi: 10.1074/mcp.M900203-MCP200. Epub 2009 Jun 29. Mol Cell Proteomics. 2009. PMID: 19567368 Free PMC article.
-
Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer.Ecancermedicalscience. 2017 Sep 18;11:768. doi: 10.3332/ecancer.2017.768. eCollection 2017. Ecancermedicalscience. 2017. PMID: 29062386 Free PMC article. Review.
-
CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.Tumour Biol. 2016 Sep;37(9):12731-12742. doi: 10.1007/s13277-016-5157-0. Epub 2016 Jul 22. Tumour Biol. 2016. PMID: 27448305
-
Matrix metalloproteinase 2/9-triggered-release micelles for inhaled drug delivery to treat lung cancer: preparation and in vitro/in vivo studies.Int J Nanomedicine. 2018 Aug 13;13:4641-4659. doi: 10.2147/IJN.S166584. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30147314 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous